A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria (B Simple)

Novo Nordisk

Status: Withdrawn

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: BIAsp 30

Study type: Observational

Funder types: Industry

Identifiers

NCT03862690

BIASP-4439

U1111-1208-5168 (Other Identifier)

Details and patient eligibility

About

The purpose of the study is to collect information about how NovoMix® 30 works in real world adult population with type 2 diabetes. Participants will get NovoMix® 30 as prescribed by the study doctor. The study will last for about 6-8 months. Participants will be asked questions about their health and their diabetes treatment as part of their study doctor's appointment.

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)
• The decision to initiate treatment with commercially available NovoMix® 30 has been made by the patient and the treating physician before and independently from the decision to include the patient in this study
• Male or female, greater than or equal to 19 years at the time of signing informed consent
• Diagnosed with type 2 diabetes and treated with basal insulin plus 1-3 bolus insulin injections per day for at least 24 weeks prior to informed consent
• Available and documented HbA1c value less than or equal to 12 weeks prior to initiation of NovoMix® 30 treatment

Exclusion criteria

• Previous participation in this study. Participation is defined as having given informed consent in this study
• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
• Participation in any clinical trial of an approved or non- approved investigational medicinal product within 24 weeks prior to initiation of NovoMix® 30 treatment. Clinical trials do not include non-interventional studies
• Hypersensitivity to NovoMix® 30 or to any of the excipients
• Pregnancy or intention of becoming pregnant

Trial design

0 participants in 1 patient group

Participants with Type 2 Diabetes Mellitus

Description:

A broad adult population of patients with type 2 diabetes (T2D) requiring insulin therapy in different basal-bolus treatment regimens.

Treatment:

Drug: BIAsp 30